Clinical Trial Update: Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a short course of bortezomib in anemic patients with refractory cold agglutinin disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cold Agglutinin Disease

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Refractory Cold Agglutinin Disease | Phase 2 | Status: COMPLETED